Skip to Main Content

Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human

The recruitment status of this study is unknown because the information has not been verified recently.

Verified September 2010 by Hallym University Medical Center.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Hallym University Medical Center

ClinicalTrials.gov Identifier:

NCT01131533

First received: May 25, 2010

Last updated: September 14, 2010

Last verified: September 2010

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	December 2011
Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Publications:

Li W, Sinclair SH, Xu GT. Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb;41(1):18-25.

Lagrèze WA, Feltgen N, Bach M, Jehle T. Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol. 2009 Dec;93(12):1667-71. Epub 2009 Aug 18.

Song BJ, Cai H, Tsai JC, Chang S, Forbes M, Del Priore LV. Intravitreal recombinant human erythropoietin: a safety study in rabbits. Curr Eye Res. 2008 Sep;33(9):750-60.

Zhang J, Wu Y, Jin Y, Ji F, Sinclair SH, Luo Y, Xu G, Lu L, Dai W, Yanoff M, Li W, Xu GT. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci. 2008 Feb;49(2):732-42.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lim JW, Han JR. Aqueous humour levels of vascular endothelial growth factor and erythropoietin in patients with diabetic macular oedema before and after intravitreal erythropoietin injection. Clin Experiment Ophthalmol. 2011 Aug;39(6):537-44. Epub 2011 Mar 24.